BIIB Jan 2024 400.000 call
| Previous close | 5.70 |
| Open | 5.70 |
| Bid | 3.40 |
| Ask | 10.00 |
| Strike | 400.00 |
| Expiry date | 2024-01-19 |
| Day's range | 5.70 - 5.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 230 |
- GlobeNewswire
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau protein (CSF t-tau and p-tau181) in the cerebral spinal fluid (CSF) throughout the open-label long-term extension (LTE)Neurofibrillary tangles in the brain are composed of tau proteins and are a key pathology associated with Alzheimer’s disease1 CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Biog
- Zacks
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
Biogen Inc. (BIIB) closed at $269.98 in the latest trading session, marking a -0.02% move from the prior day.
- Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
